AMPH (Amphastar Pharmaceuticals) Other Stockholders Equity: $-0.0 Mil (As of Mar. 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $20.46
GF Value $48.79
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Other Stockholders Equity?

Amphastar Pharmaceuticals AMPH -6.06% 83 Other Stockholders Equity is $-0.0 Mil as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Amphastar Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.0 Mil.

Amphastar Pharmaceuticals's quarterly Other Stockholders Equity increased from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($0.0 Mil) but then declined from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($-0.0 Mil).

Amphastar Pharmaceuticals's annual Other Stockholders Equity declined from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then increased from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($0.0 Mil).

Amphastar Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Other Stockholders Equity Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.0 Mil mean?
Amphastar Pharmaceuticals (AMPH) has a Other Stockholders Equity of $-0.0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Other Stockholders Equity too high?
Amphastar Pharmaceuticals' current Other Stockholders Equity is $-0.0 Mil. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Other Stockholders Equity compare to ETON and PCRX?
Amphastar Pharmaceuticals' Other Stockholders Equity of $-0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Other Stockholders Equity is $-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $20.46 — trading 58.1% below its estimated fair value. The current Other Stockholders Equity is $-0.0 Mil. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Other Stockholders Equity is $-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $20.46 is trading 58.1% below its estimated GF Value™ of $48.79. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Other Stockholders Equity: $-0.0 Mil
  • GF Value™: $48.79 vs. price of $20.46 (58.1% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price
$48.79
GF Value